Xeris Biopharma Holdings, Inc.
XERS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001867096
In the last 90 days, Xeris Biopharma Holdings, Inc. insiders filed 0 open-market purchases and 9 sales; 242 institutions reported holding it in 13F filings for Q2 2026, worth $857.1M in total; no superinvestor holds it.
Holders of 5% or more of XERS
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Xeris Biopharma Holdings, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Vanguard Capital Management LLC | 13G | 5.00%8.64M shares | New | Jul 31, 20261 filing | Jul 31, 2026 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
21 Schedule 13D and 13G filings on Xeris Biopharma Holdings, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Jul 31, 202610:41 AM ET | Vanguard Capital Management LLC | 13G | 5.00%8.64M shares | New | Jun 30, 2026 | SEC |
| Mar 27, 20262:12 PM ET | Vanguard Group Inc | 13G/A | 0.00%0 shares | −6.74 ppfrom 6.74%Below 5% | Mar 13, 2026 | SEC |
| Jan 30, 20262:43 PM ET | Vanguard Group Inc | 13G/A | 6.74%11.2M shares | – | Dec 31, 2025 | SEC |
| Feb 13, 2024 | Vanguard Group Inc | 13GOld format | – | New | – | SEC |
| Feb 13, 2024 | Stonepine Capital Management, LLC | 13G/AOld format | – | – | – | SEC |
| Jan 26, 20244:23 PM ET | BlackRock Inc. | 13GOld format | – | New | – | SEC |
| Feb 14, 2023 | Caxton Corp | 13G/AOld format | – | – | – | SEC |
| Feb 13, 2023 | Stonepine Capital Management, LLC | 13G/AOld format | – | – | – | SEC |
| Feb 10, 20239:04 AM ET | BlackRock Inc. | 13GOld format | – | New | – | SEC |
| Feb 14, 2022 | Sessa Capital (Master), L.P. | 13G/AOld format | – | – | – | SEC |
| Feb 11, 2022 | Flynn James E | 13G/AOld format | – | – | – | SEC |
| Jan 14, 2022 | Stonepine Capital Management, LLC | 13GOld format | – | New | – | SEC |
| Jan 5, 2022 | Caxton Corp | 13GOld format | – | New | – | SEC |
| Jul 12, 20218:29 AM ET | BlackRock Inc. | 13GOld format | – | – | – | SEC |
| Mar 17, 2021 | Flynn James E | 13GOld format | – | – | – | SEC |
| Feb 16, 2021 | Sessa Capital (Master), L.P. | 13G/AOld format | – | – | – | SEC |
| Feb 16, 2021 | ArrowMark Colorado Holdings LLC | 13G/AOld format | – | – | – | SEC |
| Feb 16, 2021 | Redmile Group, LLC | 13G/AOld format | – | – | – | SEC |
| Feb 12, 2021 | Flynn James E | 13G/AOld format | – | – | – | SEC |
| Feb 11, 2021 | Soros Fund Management LLCSuperinvestorSoros Fund Management | 13G/AOld format | – | – | – | SEC |
| Feb 1, 20218:30 AM ET | BlackRock Inc. | 13G/AOld format | – | – | – | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Xeris Biopharma Holdings, Inc. shares.
No Form 144 notices for Xeris Biopharma Holdings, Inc. are on file.